Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Gain on sale of PREBOOST® business

Impairment of intangible assets

Provision for (recovery of) credit losses

Gain on sale of ENTADFI® assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Veru

Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer, VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer, and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects, and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veru reports positive Phase III results for sabizabulin in COVID-19

Veru's positive Phase III trial results for sabizabulin in COVID-19 highlight its potential in reducing mortality.
Financially, challenges persist with decreased revenues and increased expenses, but the company is focused on growth strategies.
The company's strengths lie in sabizabulin's unique mechanism, clinical trial prioritization, and revenue generation plans.
Opportunities for Veru include commercializing sabizabulin, driving revenue growth, and advancing oncology trials.

Veru reports Q2 financial challenges but shows promise in clinical developments

Veru Inc. faced financial challenges in Q2 2023 with decreased net revenues and significant operating losses, prompting efforts to manage costs and explore strategic options.
Despite the financial hurdles, the company demonstrated strengths in clinical developments, securing additional funding, and pursuing growth opportunities in breast cancer and viral ARDS treatments.
Veru's focus on increasing revenues through marketing efforts, expanding distribution channels, and seeking strategic partnerships positions the company for future growth and success in the pharmaceutical industry.

Veru reports mixed Q3 results, eyes partnerships and market expansion

Veru Inc. faced challenges with a decrease in net revenues but achieved a net income for Q3 2023.
Strengths lie in promising results of enobosarm and sabizabulin studies, FDA clarity, and improved cash position.
Opportunities include expanding evaluation of sabizabulin, seeking partnerships, and market expansion through tenders.
The company needs to address challenges of net losses, high operating expenses, and maintaining adequate cash reserves.

Veru Inc. reports Q4 earnings, pursues partnerships for drug development

Veru Inc. reported a decrease in net revenues but secured significant funding through a successful public offering. Their drug development program, particularly enobosarm and sabizabulin, holds promise for multiple medical applications. The pursuit of partnerships and the potential for combination treatments present opportunities for future growth.

Veru Inc. reports Q1 growth, seeks partners for enobosarm study

Veru Inc. demonstrates financial progress and strategic initiatives in drug development, positioning itself for future growth and innovation.
The company's focus on enobosarm's potential in weight loss and oncology, along with seeking partnerships, reflects a proactive approach to advancing its pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.

  --Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021--     --VERU-111 Phase 1b Clinical Trial Results Accepted for Presentation at European Society for Medical Oncology 2020 Congress --

Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter

Aphria

DraftKings

Lockheed Martin

MGM Resorts

Altria

Boston Beer Company

If you’re able to overlook the shortcomings of these seven sin stocks, your long-term gains will be enough to soothe your conscience.

7 Sin Stocks Whose Profits Are Too Irresistible to Pass Up

--VERU-111 significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome in COVID-19 in a toxic shock model--      --VERU-111’s ability to disrupt microtubules has potential for dual drug action against COVID-19: treat SARS-CoV-2 virus infection and reduce Inflammation caused by viral infection-induced Cytokine Storm—      -- Phase 2 clinical study in hospitalized COVID-19 patients at high risk for Acute Respiratory Distress Syndrome actively enrolling patients --                 

VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19

MIAMI, July  30, 2020  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it will report financial results for its fiscal 2020 third quarter ended June 30, 2020, on Thursday, August 13, 2020 before the market opens.  Veru’s management will host a conference call that same day at 8 a.m. ET to review the Company’s performance and to answer questions.  The call will also be accessible via webcast.

Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th

MIAMI, July  27, 2020  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that the clinical results from its Phase 1b/2 study of VERU-111 have been accepted for oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 to be held September 19-21, 2020. VERU-111 is a novel, oral, first-in-class, tubulin targeting agent that crosslinks and disrupts alpha and beta tubulin subunits of microtubules. VERU-111 is in clinical development to treat metastatic castration and novel androgen receptor targeting agent (enzalutamide or abiraterone) resistant prostate cancer, a growing unmet medical need in advanced prostate cancer.

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

--Pivotal Phase 3 Clinical Trial Expected to Initiate First Quarter Calendar Year 2021-- --Pivotal Phase 3 Clinical Trial Expected to Initiate First Quarter Calendar Year 2021--

Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

MIAMI, June  29, 2020  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has been added to the Russell 2000® Index and the Russell 3000® Index, effective as of the open of the market today, following Russell's annual reconstitution of its comprehensive set of U.S. and global equity indices.

Veru Inc. Added to the Russell 2000 and 3000 Indices

Veru (VERU) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Veru (VERU) Soars: Stock Adds 6.9% in Session

--VERU-111 has potential to treat both the SARS-CoV-2 virus infection and the severe inflammation leading to acute respiratory distress syndrome-- --VERU-111 has potential to treat both the SARS-CoV-2 virus infection and the severe inflammation leading to acute respiratory distress syndrome--

Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19

Veru Inc. (VERU) CEO Mitchell Steiner on Q2 2020 Results - Earnings Call Transcript

Investors liked the drugmaker's positive Q1 update. And they liked its news about a COVID-19 clinical study even more.

Why Veru Stock Is Vaulting Higher Today

Shares of Veru (NASDAQ:VERU) rose 7% in pre-market trading after the company reported Q2 results.

Recap: Veru Q2 Earnings

--Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable PSA Declines and Tumor Regression in Phase 1b Study; Phase 2 Study Enrolling; Plan to Meet with FDA as Positive Clinical Data Supports Clinical Advancement to Pivotal Phase 3 Study--      --Unique Dual Mechanism of Action of VERU-111 Potentially Effective Against COVID-19;     FDA Grants Permission to Initiate Phase 2 Clinical Study; First Patient to be Dosed within 2 Weeks--         --Commercial Business Continues to Deliver Robust Growth--

Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%

--VERU-111’s Ability to Disrupt Microtubules has Potential for Dual Drug Action Against COVID-19: Treat SARS-CoV-2 Virus Infection and Reduce Inflammation Caused by Viral Infection-Induced Cytokine Storm--     --Phase 2 Clinical Study Expected to Commence in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome in 2 Weeks--                 

Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19

             --VERU-111 Safe and Well Tolerated at Daily Doses 63 mg and Lower; No Significant Neutropenia or Neurotoxicity Observed    --      --Evidence of antitumor activity; durable PSA declines, objective tumor regression and stable disease--

Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program

--VERU-111 Targeting Men with Metastatic Castration Resistant Prostate Cancer Who Have Also Become Resistant to Abiraterone or Enzalutamide--     --Phase 2 Study Results Expected by Calendar Year End—

Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2020 Results - Earnings Call Transcript

B2Gold

FlexShopper

Orion Energy Systems

Plug Power

SPAR Group

These small-cap stocks to buy are all under $5, but they come from industries and sectors with massive potential.

7 ‘A’-Rated Stocks Under $5 to Buy Now

-- Plans to Advance Zuclomiphene into Pivotal Phase 3 Clinical Trial in First Half of 2020 --     -- Potential to be First FDA-Approved Drug for ADT Induced Hot Flashes --

Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy

As of late, it has definitely been a great time to be an investor in Veru.

Will Veru Continue to Surge Higher?

Veru Inc. (VERU) CEO Mitchell Steiner on Q4 2019 Results - Earnings Call Transcript

-- Potential to be First FDA-Approved Drug for ADT induced Hot Flashes –

Veru Announces Full Enrollment of Phase 2 Trial in Men with Prostate Cancer Treatment Induced Hot Flashes

MIAMI, Aug.  28, 2019  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced its participation at three upcoming healthcare investor conferences.  Schedule as follows: 

Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York

MIAMI, Aug.  27, 2019  (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for prostate cancer treatment and prostate cancer supportive care, today announced that it has been invited by NASDAQ to ring the closing bell on September 4, 2019, to kick off National Prostate Cancer Awareness Month.  Veru’s Chairman, President and Chief Executive Officer, Dr. Mitchell Steiner, will be joined by company management and other guests at the closing bell ceremony.

Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month

Veru Inc. (VERU) CEO Mitchell Steiner on Q3 2019 Results - Earnings Call Transcript

News for Veru Stock (VERU)